Craig has been working with novel products for rare disorders since 2004 across multiple therapeutic areas. Craig’s expertise in life sciences strategy has been gained from over twenty years working with leading pharmaceutical companies both as an employee and as a consultant. During his time in industry, Craig led teams launching novel products. Responsible for strategy and ensuring aligned tactical implementation, he has been instrumental in driving orphan drugs to achieve blockbuster status. As a consultant, he has been called upon to develop launch strategies for orphan and biologic brands at a global and country level by some of the world’s leading rare disorder companies.